New substances and devices are cited in technology proposals.
The Inpatient Prospective Payment System (IPPS) Proposed Rule for the 2022 fiscal year (FY), which was released on April 27, includes numerous applications for New Technology Add-On Payments (NTAPs). The proposals will be finalized in the IPPS Final Rule, which should be published in early August 2021.
There is an unprecedented proposal to continue 15 items from FY 2021 that were due to be discontinued, based on the “newness” criteria. This proposal can be attributed to the COVID-19 pandemic. The items proposed to be continued include the following:
There are two items that are continued from FY 2020; they are JAKAFI, which treats graft versus host disease, and Balversa, which treats locally advanced or metastatic urothelial carcinoma. There are seven items that were continued from FY 2021; these items include the following:
There were several new proposals outlined in the proposed rule. The following items are among the new proposals – to be considered if they meet the “newness” criteria, the MS-DRG payment does not cover the cost, and they significantly impact patient outcomes.
|
Item |
Treatment Of |
|
Aidoc Briefcase |
Pulmonary embolism |
|
Amivantamab |
Metastatic non-small cell lung carcinoma |
|
Breyanzi |
Relapsed/refractory large B-cell lymphoma |
|
Ciltacabtagene autoleucel |
Multiple myeloma |
|
COSELA |
Extensive-stage small cell lung carcinoma |
|
Ellipsys Vascular Access System |
End-stage renal disease |
|
ENSPRYNG |
Neuromyelitis optica spectrum disorder |
|
ABECMA |
Relapsed/refractory multiple myeloma |
|
INDIGO Aspiration System with Lightning Aspiration Tubing |
Pulmonary embolism, deep vein thrombosis, arterial thromboembolus |
|
Ischemia Care Respiratory and Stroke Test Kit |
Cardioembolic stroke and large artery atherosclerotic stroke |
|
Lifileucel |
Metastatic melanoma |
|
Narsoplimab |
Transplant-associated thrombotic microangiopathy |
|
NexoBrid |
Eschar (non-surgical option) |
|
Olumiant |
COVID-19 |
|
Pure-Vu Cleansing System |
High-intensity, intra-procedural cleansing during colonoscopy |
|
RAPID Aspects |
Computer-aided software device used to detect abnormal brain tissue |
|
Steripath Micro Blood Collection System |
Single-use collection device for blood cultures |
|
StrataGraft Skin Tissue |
Severe thermal burns |
|
Tecartus |
Relapsed/refractory mantle cell lymphoma |
|
Terlivaz |
Hepatorenal Syndrome, Type 1 |
|
Veklury |
COVID-19 |
|
ZEPZELCA |
Metastatic small cell lung cancer |
The proposed rule also cites the New COVID-19 Treatment Add-On Payment (NC-TAP), which was implemented on Nov. 2, 2020. This provides for additional payment for items that do not qualify for NTAP, but treat COVID-19. An item cannot receive both NC-TAP and NTAP payment; if the item is approved for NTAP, then it will not receive NC-TAP. This additional payment will remain in effect until the end of the fiscal year, when the end of the pandemic is declared. For example, if the pandemic is declared over in July 2021, then the NC-TAP will end Sept. 30, 2021. If the pandemic was declared over in November 2021, then the NC-TAP would remain in effect until Sept. 30, 2022.
There are 12 items that are proposed for the New Technology Add-On Payment Alternative Pathway. These items include the following:
|
Item |
Treatment Of/ Description of Use |
|
Aprevo Intervertebral Body Fusion Device |
Stabilizes lumbar spinal column |
|
aScope Duodeno |
Single-use endoscope for upper GI procedures |
|
Caption Guidance |
Artificial intelligence-guided medical image acquisition software – cardiac ultrasound |
|
CERAMENT G |
Osteomyelitis |
|
EXALT Model DP |
Single-use duodenoscope for use during ERCP |
|
FUJIFILM EP-7000X System |
Used during thoracic, abdominal, gynecologic procedure |
|
Harmony Transcatheter Pulmonary Valve (TPV) System |
Severe pulmonary regurgitation |
|
Neovasc Reducer |
Refractory angina |
|
Phagenyx System |
Neurogenic dysphagia |
|
Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) |
Fibrinogen deficiency-related bleeding |
|
Shockwave C2 Intravascular Lithotripsy (IVL) System |
Lithotripsy-enabled, low-pressure dilation of calcified, stenotic de novo coronary arteries prior to stenting |
|
Thoraflex Hybrid Device |
Damaged/diseased aortic arch or descending aorta, with or without ascending aorta involvement |
There is one last item that has been proposed under the Qualified Infectious Disease Products (QIDP). CONTEPO is used to treat complicated urinary tract infections.
It is important to note these New Technology Add-On Payment items, as the reimbursement is paid in addition to the MS-DRG payment. These payments are triggered by the ICD-10-PCS code, unless otherwise noted in the regulations. The increased number of proposals has impacted the activity in the Coordination and Maintenance Committee meeting, as many of the new proposals have ICD-10-PCS codes requested. As you identify the items that are used by your facility, you should also identify which documentation can be used to identify the items. The items and documentation should be part of your education for IPPS FY 2022.
Programming Note: Listen to Laurie Johnson’s live coding report every Tuesday during Talk Ten Tuesdays, 10-10:30 a.m. Eastern.
Today is election day. I wanted to talk about the process by which laws are passed and regulations created in healthcare. Recently, the fall of
If you’ll recall, a couple of weeks ago, I reported on the Centers for Medicare & Medicaid Services (CMS) Proposed Rule for the social determinants
Please log in to your account to comment on this article.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
This webcast, presented by Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, a recognized expert with over 30 years of experience, offers essential strategies to improve outpatient clinical documentation integrity. You will learn how to enhance the accuracy and completeness of patient records by adopting best practices in coding and incorporating Social Determinants of Health (SDOH). The session also highlights the role of technology, such as EHRs and CDI software, in improving documentation quality. By attending, you will gain practical insights into ensuring precise and compliant documentation, supporting patient care, and optimizing reimbursement. This webcast is crucial for those looking to address documentation gaps and elevate their coding practices.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 ICD10monitor. Powered by MedLearn Media.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
👻Spooky Sale is Back!👻 Get 31% off all three Medlearn brands, using code SPOOKY24.
